The FDA has approved infliximab-dyyb as a biosimilar and not as an interchangeable biological.
The FDA has approved Inflectra (infliximab-dyyb), administered as an intravenous infusion, for multiple indications. This is biosimilar to Janssen Biotech’s Remicade (infliximab). The approval comes just over a year after the first biosimilar product, Zarxio (filgrastim-sndz), was approved by the FDA.
The indications for this second biosimilar product in the United States include:
The approval followed an FDA review of structural and functional data, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data, and other clinical safety and effectiveness data of infliximab-dyyb. The review convinced the FDA that infliximab-dyyb is biosimilar to infliximab. It is important to note that infliximab-dyyb has not been approved as an interchangeable product.
Janet Woodcock, MD, director of FDA’s Center for Drug Evaluation and Research said in a statement, “Biosimilars can provide access to important treatment options for patients who need them. Patients and the health care community can be confident that biosimilar products are high quality and meet the agency’s rigorous scientific standards.”
The cost of infliximab-dyyb will of course be an important factor that could significantly impact acceptance. A single infusion of infliximab can cost anywhere between $1300 and $2500. Unless the biosimilar is sold at a significantly lower price, shifting consumer preference could be a challenge, especially since providers and patients alike have been cautious with accepting biosimilars.
Infliximab-dyyb is manufactured by Celltrion, Inc, based in the Republic of Korea, for Hospira. It will be marketed in the United States by Pfizer.
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More